Targeted TMS@NAViGO is a novel method of the delivery of painless, non-invasive brain stimulation therapy for treatment-resistant depression and other mood disorders.
Targeted TMS offers an alternative to traditional drug-based treatments, requires no anaesthesia and carries none of the serious side effects reported for other brain stimulation remedies.
Transcranial Magnetic Stimulation (TMS) is a revolutionary technological treatment for Depression.
NAViGO has been at the forefront of the ground-breaking research regarding the application of TMS, focusing on the treatment of mood disorders.
TMS has been recommended by NICE (2015) as an effective and safe treatment in the UK for the treatment of Depression.
Innovators from around the region gathered at Cedar Court Hotel near Wakefield for a networking event and awards ceremony where five teams were crowned winners across different innovation categories: Medical Devices and Diagnostics, GP and Community Care, Mental Health and Wellbeing, Self-Management and Service Improvement.
The awards provide a platform to showcase pioneering new ideas and technologies developed by, or with, NHS staff to improve patient care and make services more efficient.
The awards are run by Medipex Ltd., the innovation hub for NHS organisations in Yorkshire and the Humber and the East Midlands. Dr Colin Robertson, Transcranial Magnetic Stimulation Practitioner for NAViGO said; “We are delighted have won this year’s Mental Health category of the Medipex NHS Innovation Awards and Showcase. This is a significant recognition for our innovative approach to achieve a better treatment outcome for mental health clients everywhere”.